Scholars Central

Conference abstractPublished 26 Jul 2018

Design and development of some novel esters of NSAIDs as prodrugs

Authors: Meghna Patel

Saurashtra University, India

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The discovery of the inducible isoform of cyclooxygenase enzyme (COX-2) spurred the search for anti-inflammatory agents devoid of the undesirable effects associated with classical NSAIDs (non-steroidal anti-inflammatory drugs). New Omeprazole ester (OM I-IV) and Rabeprazole ester (RH I-IV) prodrugs of some acidic NSAIDs (IâÂ?Â?IV) were designed, synthesized and evaluated as mutual prodrugs with the aim of improving the therapeutic potency and retard the adverse effects of gastrointestinal origin. The structure of the synthesized mutual ester prodrugs were confirmed by melting point, IR, 1H NMR, mass spectroscopy (MS) and their purity was ascertained by TLC and elemental analyses. The logP values of the NSAIDs (IâÂ?Â? IV), omeprazole, rabeprazole, hydroxymethyl omeprazole (OM), hydroxymethyl rabeprazol (RH) and the target derivatives (OM I-IV & RH I-IV) were measured by routine shake flask method and computed for logP (ClogP) contained in a PCsoftware package. Hydrolysis study of synthesized prodrugs were also done by validated HPLC method to ensure that release of parent drugs. Ester prodrugs were evaluated for their in-vitro anti-inflammatory activity by inhibition of bovine serum albumin denaturation. Synthesized prodrugs showed satisfactory anti-inflammatory activity.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Drug Designing: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalDrug Designing: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Meghna Patel”